Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sandbrink

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Biological Chemistry|May 31, 1996
Alzheimer's disease betaA4 protein release and amyloid precursor protein sorting are regulated by alternative splicingT Hartmann, C Bergsdorf, R Sandbrink, et al.
Molecular Psychiatry|December 17, 1997
Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imagingJ Schröder, J Pantel, N Ida, et al.
Neurology|November 30, 2006
Blockade of chemokine signaling in patients with multiple sclerosisF Zipp, H P Hartung, J Hillert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 10, 2008
Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosisI J van den Elskamp, J Lembcke, V Dattola, et al.
Neurology|August 18, 2006
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesL Kappos, C H Polman, M S Freedman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFITG Edan, L Kappos, X Montalbán, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2007
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging resultsJ M Nielsen, B Moraal, C H Polman, et al.
Neuroradiology|January 6, 2010
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosisI J van den Elskamp, B Boden, V Dattola, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 31, 2010
Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosisI J van den Elskamp, D L Knol, H Vrenken, et al.
Neurology|August 19, 2011
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndromeH-P Hartung, M S Freedman, C H Polman, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Biological Chemistry|May 31, 1996
Alzheimer's disease betaA4 protein release and amyloid precursor protein sorting are regulated by alternative splicingT Hartmann, C Bergsdorf, R Sandbrink, et al.
Molecular Psychiatry|December 17, 1997
Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imagingJ Schröder, J Pantel, N Ida, et al.
Neurology|November 30, 2006
Blockade of chemokine signaling in patients with multiple sclerosisF Zipp, H P Hartung, J Hillert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 10, 2008
Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosisI J van den Elskamp, J Lembcke, V Dattola, et al.
Neurology|August 18, 2006
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesL Kappos, C H Polman, M S Freedman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFITG Edan, L Kappos, X Montalbán, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2007
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging resultsJ M Nielsen, B Moraal, C H Polman, et al.
Neuroradiology|January 6, 2010
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosisI J van den Elskamp, B Boden, V Dattola, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 31, 2010
Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosisI J van den Elskamp, D L Knol, H Vrenken, et al.
Neurology|August 19, 2011
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndromeH-P Hartung, M S Freedman, C H Polman, et al.
Pageof 4